Press release
Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria.\n\n\nDetails for the ECCO presentations are as follows:\n\n\nSession Type: Poster Exhibition\nSection Title: Basic Science\nSession Date and Time: Friday, February 14, 2020; 12:30- 1:30 p.m. CET\nPoster Number: P034\nPoster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor, Induces HIF-1α Target Genes and is Efficacious in Mouse Colitis\nPresenter Name: Kristen Talyor Meadows, Ph.D.\nLocation: Hall C – Reed Messe Vienna Congress Center\n\n\nSession Type: Poster Exhibition\nSection Title: Clinical: Therapy and Observation\nSession Date and Time: Friday, February 14, 2020; 12:30- 1:30 p.m. CET\nPoster Number: P540\nPoster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First In-Human Multiple Dose Study in Healthy Subjects With Gut Biopsies\nPresenter Name: Barrett Levesque, M.D.\nLocation: Hall C – Reed Messe Vienna Congress Center\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200213005151/en/\n\nFor Investors:\nArgot Partners\nTel 212.600.1902\[email protected]\n\n\nFor Media:\nArgot Partners\nDavid Rosen\nTel 212.600.1902\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3801,"tagName":"div"}]